Cancer research moves fast. We make it understandable.
In the prospective, 20,176-participant BLUE-C study, Cologuard Plus (a next-generation multitarget stool DNA test) detected colorectal cancer with 95% sensitivity and correctly identified 94% of participants without colorectal cancer or…
Primary source cited
Last reviewed
A peer-reviewed case series describing three patients who self-administered fenbendazole (a veterinary dewormer, not an approved human cancer drug) alongside their standard cancer treatment, and reported remission, was published in…
Primary source cited
Last reviewed
In the randomized, phase 2b KEYNOTE-942 trial, adding a personalized mRNA cancer vaccine (manufactured for each patient's own tumor mutations) to pembrolizumab reduced the risk of melanoma recurrence or death…
Primary source cited
Last reviewed
In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON…
Primary source cited
Last reviewed
In the randomized, phase 3 IMvigor011 trial, atezolizumab reduced the risk of disease recurrence or death by 36% and the risk of death by 41% compared with placebo, specifically in…
Primary source cited
Last reviewed
In the single-arm, open-label C-144-01 trial, a one-time infusion of a patient's own expanded tumor-infiltrating lymphocytes (lifileucel) produced an objective response in 31.5% of patients with advanced melanoma who had…
Primary source cited
Last reviewed
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
In experimental/preclinical models, a tardigrade-protein-inspired, nanoparticle-delivered mRNA strategy reduced radiation-induced DNA damage in oral and rectal tissue.
Primary source cited
Last reviewed
In a large randomized trial (105,934 participants), AI-supported mammography reading achieved a lower interval-cancer rate than standard double reading (1.55 vs. 1.76 per 1,000, meeting noninferiority) with higher sensitivity (80.5%…
Primary source cited
Last reviewed
A single glioblastoma patient's response to neoadjuvant checkpoint immunotherapy has prompted a formal randomized Phase II trial (GIANT, at Duke University, testing nivolumab with or without relatlimab).
Primary source cited
Last reviewed